Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Delivery
- Respiratory
- Disease
- Pharmaceuticals
- Device
- Cannabis
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 319351
License Grant
Licensor (of the United Kingdom) granted Licensee the exclusive North American license to develop and commercialize a High-Density Molecular Masking Spray (MMS019) as an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans.
License Property
MMS019 is a High-Density Molecular Masking Spray developed as an anti-viral barrier to potentially prevent or reduce the risk or the intensity of viral infections in humans. This formulation is to be delivered using a preassembled device and cartridge to propel the High-Density Molecular Spray formulation into the nose.
Field of Use
The field of use is for a nasal powder spray to potentially prevent viral binding to epithelial cells in the nasal cavity and the upper respiratory tract to protect healthcare workers, and those at-risk of serious disease, from viral infections.
MMS019 will be used as a nasal powder spray to prevent viral binding to epithelial cells in the nasal cavity and the upper respiratory tract, which could significantly reduce respiratory related infections.
Among other uses, MMS019 is being developed to prevent SARS-COV-2 binding and entry to respiratory epithelial cells, by binding to epithelial cells in the nasal cavity and the upper respiratory tract. Virpax believes MMS019 may offer another layer of protection, in the form of a Molecular Mask, to be added to standard personal protective equipment to protect healthcare workers, and those at-risk of contracting serious diseases, from infection.
IPSCIO Record ID: 1165
License Grant
The license agreement assigns to the Licensee, Viratek’s exclusive license from a University covering the aerosol device used to deliver ribavirin (Virazole(R)) to the lungs.
License Property
VIRAZOLE® is indicated for the treatment of hospitalized infants and young children with severe lower respiratory tract infections due to Respiratory Syncytial Virus (RSV). Treatment early in the course of severe lower respiratory tract infection may be necessary to achieve efficacy.
Field of Use
Ribavirin is an anti-viral drug indicated for severe RSV infection (individually), hepatitis C infection (used in conjunction with peginterferon alfa-2b or peginterferon alfa-2a), and other viral infections.
IPSCIO Record ID: 315783
License Grant
The Israelis Company received an exclusive global license to purchase Israelis Licensor products for the purpose of reselling the products, focusing on a unique Biogel for the protection from COVID-19 virus.
License Property
BioGel products are a blend of all natural organic herbs and minerals without the potential side-effects of any antibiotics or steroids to mitigate biological threats such as SARS-CoV-2, COVID-19, bacteria and more.
Company developed an innovative Capture & Contain technology, designed to safely prevent allergens and virus intrusion through the upper airways and eye cavities. Company’s technology is comprised of a Biogel that is applied topically, is preventative, safe, easy to use and can be formulated both for wet and dry administration.
Company’s goal is to provide protection from the spread and contamination of Coronavirus inhaled or absorbed through the upper airways and eyes. The final product shall take the form of a spray or eyedrops, made of mucoadhesive biological gel (a gel that contains covalently bound specific Abs against SARS-CoV-2 specific surface proteins) aiming to lower the intrusion levels of the virus through the nasal and buccal cavities for several hours.
Field of Use
The rights granted are for the purpose of reselling the products worldwide. The products are developed to provide protection from the spread and contamination of Coronavirus inhaled through the upper airways and eyes, using spray or eyedrops made of mucoadhesive biological gel (a gel that contains covalently bound specific Abs against SARS-CoV-2 specific surface proteins), aiming to lower the intrusion levels of the virus through the nasal and buccal cavities for several hours. Similarly, the products may provide protection from airborne allergens through the upper airways and eyes, reducing the allergic reaction due to a lower amount of allergens reaching its target cells.
IPSCIO Record ID: 377097
License Grant
Licensee entered into a collaboration with Licensor of the United Kingdom for the exclusive worldwide license to develop and commercialize an investigational formulation delivered via the nasal route to enhance pharmaceutical-grade cannabidiol (CBD) transport to the brain to potentially treat seizures associated with tuberous sclerosis complex (TSC),
License Property
VRP324, the first investigational formulation delivered via the nasal route to enhance CBD transport to the brain. VRP324 uses a preassembled device and cartridge to propel the CBD powder formulation into the nose to the brain via the olfactory nerve/bulb.
VRP324 is a drug product candidate based on nanotechnology which enables the delivery of CBD into the brain via intranasal delivery for the management of seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older, as well as patients one year of age and older who experience seizures associated with Lennox-Gastaut syndrome ( LGS) or Dravet syndrome. VRP324 is manufactured using high pressure homogenization and spray drying. In animal studies, the MET nanoparticles are well-tolerated via the nasal route at the dose administered.
Field of Use
The rights are to use Licensor’s molecular envelope platform technology (MET) for the nasal delivery of a cannabidiol (CBD) for the management of epilepsy in adults and children.
Field of use is for the treatment of seizures associated with tuberous sclerosis complex (TSC) Lennox-Gastaut syndrome and Dravet syndrome in patients one year of age and older.
Lennox-Gastaut syndrome and Dravet syndrome are rare central nervous system diseases considered serious epileptic encephalopathies that cause different types of epileptic seizures as well as cognitive and behavioral changes and are generally resistant to treatment.
Tuberous sclerosis complex (TSC) is a hereditary condition associated with changes in the skin, brain, kidney, and heart. Seizures are a frequent complication, and some people with TSC have learning disabilities. Skin changes are the most noticeable sign of TSC and appear in nearly all people with the condition.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
